- Compass Pathways partners with HealthPort to explore delivery of COMP360 psilocybin treatment in underserved communities.
- The collaboration focuses on addressing barriers to mental healthcare access and refining treatment implementation strategies.
- COMP360 is under investigation for treatment-resistant depression and has received Breakthrough Therapy designation from the FDA.
Compass Pathways plc (CMPS, Financial), a biotechnology company dedicated to advancing mental health treatment, announced a strategic collaboration with HealthPort, a comprehensive community health organization. This initiative aims to explore the delivery of COMP360, a synthesized psilocybin treatment, to underserved communities in the United States, contingent upon FDA approval.
The collaboration with HealthPort, which employs an integrated care model focusing on social determinants of health, will provide insights into the potential implementation of COMP360. This effort reflects a broader strategy by Compass to address the challenges and barriers impacting equitable access to innovative mental health treatments.
HealthPort has been an established entity for 45 years, operating in Maryland with a focus on behavioral health conditions, poverty, disability, and trauma. By aligning with Compass, HealthPort will help assess how COMP360 might be integrated within community care settings and contribute to research on training and care reimbursement processes, should the treatment receive regulatory approval.
This partnership is part of Compass's extensive collaboration network aiming to integrate COMP360 into diverse healthcare delivery systems. With Breakthrough Therapy designation from the US FDA for treatment-resistant depression, COMP360 represents a significant potential advancement in mental health care, promising a new treatment paradigm for difficult-to-treat conditions.
